EW
Edwards Lifesciences Corp
$89.79
장중 · Vol 89.6K · 52주 $72.30–$96.29 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $90.47 · Aug 31, 2026
EW 가격 추세
종가
$90.47
시가
$89.98
고가
$90.69
저가
$89.32
30초 브리핑
EW 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 73%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 26.9배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.1배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
EW 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
One Edwards Way · Irvine, CA, United States · 직원 16,000명
시가총액
$52.31B
Trailing P/E
53.7
최근 12개월 이익 기준
Forward P/E
26.9
이익 증가 기대 반영
EPS (TTM)
$1.68
배당 수익률
—
배당성향
0.0%
베타
0.85
시장과 유사
ROE
9.2%
P/B
4.93
EV/EBITDA
24.3
52주 범위
$72.30 – $96.29
현재 위치 73%
거래량
2.08M
20일 평균 1.82M · 1.1배
애널리스트 의견
매수 75%
총 28명 · 0m
DITM LEAPS Analysis
EW 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EW280121C00055000 | 1/21/28 · 1.4Y | $55.00 | $37.50 | 2.2x | 0.9031 | 4.7% | 10.67% | 46.64% | 0 | 81.61 | |
| EW280121C00060000 | 1/21/28 · 1.4Y | $60.00 | $33.90 | 2.4x | 0.8805 | 9.3% | 8.26% | 44.03% | 1 | 78.44 | |
| EW280121C00070000 | 1/21/28 · 1.4Y | $70.00 | $28.75 | 2.5x | 0.7988 | 27.8% | 15.65% | 50.80% | 89 | 62.86 | |
| EW280121C00075000 | 1/21/28 · 1.4Y | $75.00 | $25.50 | 2.7x | 0.7670 | 38.2% | 15.69% | 48.40% | 88 | 55.54 | |
| EW280121C00077500 | 1/21/28 · 1.4Y | $77.50 | $23.80 | 2.9x | 0.7504 | 44.3% | 15.13% | 46.66% | 2 | 47.96 |
재무제표
EW 연간 손익·현금흐름·재무상태
매출 성장률
+11.5%
최근 연간 YoY
EPS 성장률
-73.7%
최근 연간 YoY
영업이익률
27.0%
최근 연간
FCF 마진
22.0%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $6.07B+11.5% | $5.44B+8.6% | $5.01B+12.2% | $4.46B |
| 매출총이익 | $4.73B+9.5% | $4.32B+7.2% | $4.03B+7.8% | $3.74B |
| 영업이익 | $1.64B+10.5% | $1.48B-0.4% | $1.49B-3.4% | $1.54B |
| 순이익 | $1.07B-74.3% | $4.17B+197.7% | $1.40B-7.9% | $1.52B |
| 희석 EPS | $1.83-73.7% | $6.97+203.0% | $2.30-5.7% | $2.44 |
| EBITDA | $1.45B-15.9% | $1.72B+12.3% | $1.53B-8.5% | $1.68B |
| 영업현금흐름 | $1.60B+194.2% | $542.30M-39.5% | $895.80M-26.5% | $1.22B |
| 잉여현금흐름 | $1.33B+413.7% | $259.90M-58.7% | $629.50M-34.0% | $953.40M |
| 총자산 | $13.70B+4.9% | $13.06B+39.4% | $9.36B+12.9% | $8.29B |
| 총부채 | $705.40M+0.8% | $700.00M+2.2% | $685.10M-0.9% | $691.30M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
EW 실적·배당 일정
매출 하단
$1.65B
EPS 하단
$0.72
매출 상단
$1.71B
실적 발표일
2026-10-29
D-58
EPS 상단
$0.77
매출 컨센서스
$1.68B
EPS 컨센서스
$0.74
뉴스
EW 관련 최신 기사
일반Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.
Barchart · Aug 31, 2026
제품·기술Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Insider Monkey · Aug 28, 2026
실적Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · Aug 27, 2026
M&AKKR to Pay Record Settlement in Premerger-Filings Case
The amount KKR agreed to pay to settle a case with the Justice Department alleging that the private-equity giant withheld and altered documents in premerger filings. The previous record, a $12 million penalty, was collectively held by Edwards Lifesciences and Genesis MedTech. The DOJ said late yesterday that KKR failed to make complete and accurate filings for at least 16 deals in 2021 and 2022.
The Wall Street Journal · Aug 27, 2026
실적MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
Zacks · Aug 26, 2026
일반Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
Zacks · Aug 21, 2026
제품·기술Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...
Simply Wall St. · Aug 20, 2026
- 일반
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
Zacks · Aug 20, 2026
제품·기술Should You Hold Edwards Lifesciences Stock in Your Portfolio?
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Zacks · Aug 20, 2026
- 실적
Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings
Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...
Simply Wall St. · Aug 20, 2026
홀더
EW 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
96.2%
기관 보유 (유동주식)
96.4%
내부자 보유
0.2%
기관 수
1,920
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 58.79M | $5.34B | 10.2% | 11.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 37.62M | $3.41B | 6.5% | -0.3% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 26.41M | $2.40B | 4.6% | 0.0% | Jun 30, 2026 |
| State Street Corporation | 26.32M | $2.39B | 4.6% | 0.1% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 22.78M | $2.07B | 4.0% | 4.8% | Jun 30, 2026 |
| Wellington Management Group, LLP | 16.83M | $1.53B | 2.9% | -23.5% | Jun 30, 2026 |
| Geode Capital Management, LLC | 15.44M | $1.40B | 2.7% | 17.5% | Jun 30, 2026 |
| Bank Of New York Mellon Corporation | 14.08M | $1.28B | 2.5% | -15.8% | Jun 30, 2026 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 13.00M | $1.18B | 2.3% | 1.5% | Jun 30, 2026 |
| Ninety One UK Ltd | 12.34M | $1.12B | 2.1% | -0.5% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.